secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001818331-25-000121
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director
--------------------------------------------------------------------------------

- Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.
- Dr. Fuchs serves as SVP and Chief AI Officer at Eli Lilly, leading AI for drug discovery and clinical trials.
- Initial RSU grant of $420,000 vesting over three years under non-employee director compensation policy.
- Dr. Fuchs holds a doctorate in machine learning from ETH Zurich and founded Paige AI.
- No transactions requiring disclosure under Item 404(a) and no arrangements with any person.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000121/0001818331-25-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000121/wgs-20250917.htm
  HTML page:      https://secwatch.observer/filing/0001818331-25-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer